The in vitro antitumor activity of Siegesbeckia glabrescens against ovarian cancer through suppression of receptor tyrosine kinase expression and the signaling pathways

Cho,Young-Rak; Choi,Shin  Wook; Seo,Dong-Wan

doi:10.3892/or.2013.2468

The in vitro antitumor activity of Siegesbeckia glabrescens against ovarian cancer through suppression of receptor tyrosine kinase expression and the signaling pathways

Authors:
- Young-Rak Cho
- Shin Wook Choi
- Dong-Wan Seo
View Affiliations

Affiliations: College of Pharmacy, Dankook University, Cheonan 330-714, Republic of Korea, Radiant Research Institute, Radiant Inc., Chuncheon 200-883, Republic of Korea
Published online on: May 15, 2013 https://doi.org/10.3892/or.2013.2468
Pages: 221-226

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Siegesbeckia glabrescens (SG) Makino (Compositae) has been used as a traditional medicine for the treatment of a variety of diseases such as allergy, inflammation, acute hepatitis and hypertension. The primary aim of this study was to determine whether the ethanol extract of SG has antitumor activity against ovarian cancer and to identify molecular mechanisms and targets involved in the regulation of cell growth and progression. We demonstrate that SG treatment inhibits proliferation, adhesion, migration and invasion of SKOV-3 human ovarian cancer cells. The anti-proliferative effect of SG on SKOV-3 cells is accompanied by reduced expression of cyclin E and enhanced expression of the cyclin-dependent kinase inhibitor p27Kip1, leading to inhibition of pRb phosphorylation. We also show that these antitumor activities are found to be mediated through suppression of FAK, ERK, Akt and p70S6K-dependent signaling pathways and downregulation of receptor tyrosine kinases such as EGFR, VEGFR-2 and FGFR-1 as well as the cell adhesion molecule N-cadherin. Taken together, our findings suggest further development and evaluation of SG for the treatment of ovarian cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Lemmon MA and Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010. View Article : Google Scholar : PubMed/NCBI
3	Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 5:341–354. 2005. View Article : Google Scholar : PubMed/NCBI
4	Alper Ö, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K and Stetler-Stevenson WG: Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst. 93:1375–1384. 2001.PubMed/NCBI
5	van der Bilt ARM, de Vries EGE, de Jong S, Timmer-Bosscha H, van der Zee AGJ and Reyners AKL: Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. Crit Rev Oncol Hematol. 84:224–242. 2012.
6	Masoumi Moghaddam S, Amini A, Morris D and Pourgholami M: Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 31:143–162. 2012.PubMed/NCBI
7	Cole C, Lau S, Backen A, et al: Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther. 10:495–504. 2010. View Article : Google Scholar : PubMed/NCBI
8	Gui T and Shen K: The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol. 36:490–496. 2012. View Article : Google Scholar : PubMed/NCBI
9	Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
11	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
12	Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 172:973–981. 2006. View Article : Google Scholar : PubMed/NCBI
13	Bourboulia D and Stetler-Stevenson WG: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 20:161–168. 2010. View Article : Google Scholar : PubMed/NCBI
14	Kang BK, Lee EH and Kim HM: Inhibitory effects of Korean folk medicine ‘Hi-Chum’ on histamine release from mast cells in vivo and in vitro. J Ethnopharmacol. 57:73–79. 1997.
15	Kim H-M, Lee J-H, Won J-H, et al: Inhibitory effect on immunoglobulin E production in vivo and in vitro by Siegesbeckia glabrescens. Phytother Res. 15:572–576. 2001. View Article : Google Scholar : PubMed/NCBI
16	Kim JY, Lim HJ and Ryu J-H: In vitro anti-inflammatory activity of 3-O-methyl-flavones isolated from Siegesbeckia glabrescens. Bioorg Med Chem Lett. 18:1511–1514. 2008. View Article : Google Scholar
17	Li H, Kim JY, Hyeon J, Lee HJ and Ryu J-H: In vitro antiinflammatory activity of a new Sesquiterpene lactone isolated from Siegesbeckia glabrescens. Phytother Res. 25:1323–1327. 2011.
18	Jun SY, Choi YH and Shin HM: Siegesbeckia glabrescens induces apoptosis with different pathways in human MCF-7 and MDA-MB-231 breast carcinoma cells. Oncol Rep. 15:1461–1467. 2006.
19	Cho Y-R, Kim SH, Ko HY, Kim M-D, Choi SW and Seo D-W: Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70^S6K-dependent VEGFR-2 expression. Oncol Rep. 26:861–867. 2011.PubMed/NCBI
20	Seo D-W, Saxinger WC, Guedez L, Cantelmo AR, Albini A and Stetler-Stevenson WG: An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo. Peptides. 32:1840–1848. 2011. View Article : Google Scholar : PubMed/NCBI
21	Kim SH, Cho Y-R, Kim H-J, et al: Antagonism of VEGF-A-induced increase in vascular permeability by an integrin α3β1-Shp-1-cAMP/PKA pathway. Blood. 120:4892–4902. 2012.PubMed/NCBI
22	Yoon HJ, Cho Y-R, Joo J-H and Seo D-W: Knockdown of integrin α3β1 expression induces proliferation and migration of non-small cell lung cancer cells. Oncol Rep. 29:662–668. 2013.
23	Kim SH, Cho Y-R, Kim M-D, Kim HJ, Choi SW and Seo D-W: Inhibitory effects of sepiapterin on vascular endothelial growth factor-A-induced proliferation and adhesion in human umbilical vein endothelial cells. Arch Pharm Res. 34:1571–1577. 2011. View Article : Google Scholar : PubMed/NCBI
24	Cho Y-R, Choi S and Seo D-W: Sepiapterin regulates cell proliferation and migration: its association with integrin α3β1 and p53 in human lung cancer cells. Genes Genom. 33:577–582. 2011.
25	Bourboulia D, Jensen-Taubman S, Rittler MR, et al: Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment. Am J Pathol. 179:2589–2600. 2011. View Article : Google Scholar
26	Hong SY, Cho JY and Seo D-W: Ginsenoside Rp1 inhibits proliferation and migration of human lung cancer cells. Biomol Ther. 19:411–418. 2011. View Article : Google Scholar
27	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
28	Mitra SK, Hanson DA and Schlaepfer DD: Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 6:56–68. 2005. View Article : Google Scholar : PubMed/NCBI
29	Desgrosellier JS and Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar : PubMed/NCBI
30	Slack-Davis JK, Atkins KA, Harrer C, Hershey ED and Conaway M: Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res. 69:1469–1476. 2009. View Article : Google Scholar : PubMed/NCBI
31	Eliceiri BP: Integrin and growth factor receptor crosstalk. Circ Res. 89:1104–1110. 2001. View Article : Google Scholar : PubMed/NCBI
32	Hannigan GE, McDonald PC, Walsh MP and Dedhar S: Integrin-linked kinase: Not so ‘pseudo’ after all. Oncogene. 30:4375–4385. 2011.
33	Lu Y-M, Rong M-L, Shang C, et al: Suppression of HER-2 via siRNA interference promotes apoptosis and decreases metastatic potential of SKOV-3 human ovarian carcinoma cells. Oncol Rep. 29:1133–1139. 2013.PubMed/NCBI